Digital Infuzion News

Wednesday, September 16, 2015

Digital Infuzion Announces MPS I LSD Registry with Genzyme, a Sanofi Company

Mucopolysaccharidosis type I (MPS I) is a rare genetic disease that causes the progressive damage of cells in the body due to the absence of the alpha-L-iduronidase enzyme. MPS I is part of a larger group of disorders known as Lysosomal Storage Disorders (LSDs), affects about 1 in 25,000 newborns and ranges in severity from severe to attenuated.

With the recent launch of the MPS I disease registry, Genzyme's LSD registries have completed their transition to Digital Infuzion’s N of 1 Disease Management Analytics platform. RegistryNXT! a product of a long standing partnership between Genzyme and Digital Infuzion, is comprised of Gaucher, Fabry, Pompe, and MPS I disease registries and will enable clinicians and researchers to better understand Lysosomal Storage Disorders and produce therapies that will improve patient outcomes.

Learn more about Digital Infuzion's N of 1 platform by clicking here


Categories: All Digital Infuzion News, Client News, Observational OutcomesNumber of views: 4315